Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
65.71
+3.15 (5.04%)
May 27, 2025, 3:57 PM - Market open
5.04%
Market Cap 11.38B
Revenue (ttm) 803.32M
Net Income (ttm) -721.31M
Shares Out 173.12M
EPS (ttm) -4.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,454,817
Open 64.65
Previous Close 62.56
Day's Range 63.88 - 68.75
52-Week Range 22.89 - 91.45
Beta n/a
Analysts Buy
Price Target 63.90 (-2.75%)
Earnings Date May 6, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $63.9, which is a decrease of -2.75% from the latest price.

Price Target
$63.9
(-2.75% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus AI: Firing On All Cylinders

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting revenue and backlog. The AI precision medicine company grew core revenues 32%...

2 days ago - Seeking Alpha

These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut.

Lingotto Innovation's James Anderson and Morgan Samet favor companies with explosive growth potential and a focus on innovation.

4 days ago - Barrons

Tempus AI: I Believe In The Company's Cause

I initiate coverage of Tempus AI, Inc. with a Buy rating, driven by its unique data assets and AI-powered oncology solutions. The company posted strong revenue growth and margin expansion, though prof...

5 days ago - Seeking Alpha

Tempus to Present at the William Blair 45th Annual Growth Stock Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the William Blair 45th Annu...

6 days ago - Business Wire

Tempus: Is This Ultra-Fast-Growing Company A Good Investment?

Tempus AI, Inc. is growing rapidly in healthcare tech, especially genomics, but is not yet profitable and carries significant risk. Recent revenue growth is boosted by the Ambry Genetics acquisition; ...

6 days ago - Seeking Alpha

Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to develop a co...

Other symbols: VSTM
7 days ago - Business Wire

Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new strategic collaboration t...

13 days ago - Business Wire

Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle

The AI in Clinical Trials Market is driven by the surge in chronic diseases and increased pharma collaborations. Valued at $1.35 billion in 2024, it aims to reach $3.33 billion by 2032. North America ...

13 days ago - GlobeNewsWire

Tempus Announces Six Posters Accepted for Presentation at ISPOR 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, ...

13 days ago - Business Wire

Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals

JP Morgan analyst Rachel Vatnsdal reiterated the Neutral rating on Tempus AI, Inc. TEM on Wednesday, with a price forecast of $55.

19 days ago - Benzinga

Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Liz Krutoholow – Vice President-Investor Relations Eric Lefkofsky – Founder and Chief Executi...

20 days ago - Seeking Alpha

Tempus Reports First Quarter 2025 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

20 days ago - Business Wire

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the launch of Notetaker, an AI-po...

22 days ago - Business Wire

Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, is leveraging its TIME Network to expand its su...

26 days ago - Business Wire

Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Anal...

4 weeks ago - Business Wire

Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced Tempus Loop, a new oncology-foc...

4 weeks ago - Business Wire

Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including on...

4 weeks ago - Business Wire

Tempus to Report First Quarter 2025 Financial Results on May 6

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on...

4 weeks ago - Business Wire

Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced multi-year, strategic collabora...

Other symbols: AZN
4 weeks ago - Business Wire

Tempus AI: Cooldown Arrived (Rating Upgrade)

Tempus AI is trading near yearly lows despite strong growth prospects, driven by the Ambry Genetics acquisition and robust organic growth. The company has innovative AI diagnostic services, including ...

5 weeks ago - Seeking Alpha

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Adviso...

5 weeks ago - Business Wire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...

Other symbols: ILMN
6 weeks ago - PRNewsWire

Is it safe to buy the Tempus AI stock dip now?

Tempus AI stock price remains in a deep bear market as investors worry that the hype that drove it to a record high was ending. The TEM stock initially peaked at $91.40 in February, and has now plunge...

6 weeks ago - Invezz

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exh...

2 months ago - Business Wire

Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual...

2 months ago - Business Wire